 |
3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one |
|---|---|
| Trade Name | |
| Orphan Indication | Von Hippel-Lindau syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2000-03-23 00:00:00 |
| Sponsor | Sugen, Inc.;230 East Grand Ave.;South San Francisco, California, 94080 |
